These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2684001)

  • 1. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
    Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
    Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases.
    Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K
    Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical characterization of ovarian borderline tumors of intestinal and mullerian types.
    Rutgers JL; Bell DA
    Mod Pathol; 1992 Jul; 5(4):367-71. PubMed ID: 1495942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunohistochemical demonstration of CA 125, CA 19-9 and CEA in normal and pathologically changed adnexa].
    Neunteufel W; Breitenecker G
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):334-7. PubMed ID: 3165079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
    Oishi T; Maruo T; Iwasaki M; Mochizuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood group substance, CEA, and lectins in ovarian tumors.
    Dietel M; Arps H; Hölzel F; Viale G; Dell'Orto P; Kröger A; Niendorf A
    Cancer Detect Prev; 1986; 9(5-6):511-20. PubMed ID: 3465441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carcinoma with low malignant potential (borderline tumor) of the ovary: immunomorphology and clinical aspects].
    Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
    Arch Gynecol Obstet; 1989; 245(1-4):600-2. PubMed ID: 2679431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
    Neunteufel W; Breitenecker G
    Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of epithelial membrane antigen in the diagnosis of ovarian tumors.
    Fujimoto I; Hirai Y; Hasumi K; Masubuchi K; Osamura Y
    Acta Cytol; 1990; 34(4):549-54. PubMed ID: 1695804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucinous tumors of the ovary: a review.
    Hart WR
    Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies.
    van Niekerk CC; Vooijs P; Casparie-van Velsen IJ; Poels LG
    Cancer Detect Prev; 1997; 21(3):247-57. PubMed ID: 9167042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoembryonic antigen (CEA) and gastrointestinal cancer associated antigen CA 19-9 in bronchioloalveolar carcinomas and pulmonary adenocarcinomas.
    Heikkilä L; Suomalainen RJ; Lindgren J; Jalanko H; Harjula A; Mattila S
    Ann Chir Gynaecol; 1986; 75(5):260-5. PubMed ID: 3030184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.